Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
2.940
-0.460 (-13.53%)
At close: Aug 14, 2026, 4:00 PM EDT
2.990
+0.050 (1.70%)
After-hours: Aug 14, 2026, 7:55 PM EDT
Aptevo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
33
Market Cap
3.66M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 3.11M | -9.18M | -74.67% |
| Dec 31, 2021 | 12.29M | 7.98M | 185.26% |
| Dec 31, 2020 | 4.31M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 23.07M | 8.41M | 57.37% |
| Dec 31, 2017 | 14.66M | 4.67M | 46.80% |
| Dec 31, 2016 | 9.99M | -23.62M | -70.28% |
| Dec 31, 2015 | 33.60M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Curis | 7.06M |
| Ensysce Biosciences | 4.50M |
| PMGC Holdings | 1.27M |
| SciSparc | 856.00K |
| Silo Pharma | 72.10K |
| Creative Medical Technology Holdings | 3.00K |
| Alaunos Therapeutics | 3.00K |
APVO News
- 20 hours ago - Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results - Accesswire
- 1 day ago - Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds - Accesswire
- 2 days ago - Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds - Accesswire
- 18 days ago - Aptevo files patent application for Nectin-4 x PD-L1 dual-targeting backbone - TheFly
- 18 days ago - Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone - Accesswire
- 6 weeks ago - Aptevo Therapeutics awarded $1.5M research grant from Andy Hill CARE Fund - TheFly
- 6 weeks ago - Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors - Accesswire
- 2 months ago - Aptevo Therapeutics appoints Janatpour as SVP, CSO - TheFly